Analyzing Capital Efficiency: Stoke Therapeutics, Inc. (NASDAQ: STOK) Outperforms Biopharma Peers in ROIC/WACC

• Stoke Therapeutics' capital efficiency is assessed by comparing its Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC).
• Despite a negative ROIC, common for clinical-stage biopharma companies, Stoke Therapeutics' ROIC/WACC ratio stands at -4.63.
• Stoke Therapeutics demonstrates superior capital efficiency compared to its peers, including Revolution Medicines, Gossamer Bio, and Atreca, Inc.

Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biopharmaceutical company developing therapies for severe genetic disorders. The biopharma sector is capital-intensive, meaning it requires significant funding for research and development. For investors, understanding how efficiently a company like Stoke Therapeutics uses its capital is a key part of analysis.

To measure this, investors often compare Return on Invested Capital (ROIC) to the Weighted Average Cost of Capital (WACC). ROIC measures how much profit a company generates from the money invested in it. WACC is the average cost a company pays to fund its operations. A company creates value if its ROIC is higher than its WACC.

Stoke Therapeutics currently has an ROIC of -45.41% and a WACC of 9.80%. A negative ROIC is common for companies in the clinical stage, as they invest heavily in research before generating revenue. The relationship between these two numbers gives a ROIC/WACC ratio of -4.63 for Stoke Therapeutics.

When compared to its peers, Stoke Therapeutics shows a more favorable level of capital efficiency. For example, Revolution Medicines has a ROIC/WACC ratio of -6.44, while Gossamer Bio’s ratio is much lower at -35.84. Atreca, Inc. also trails with a ratio of -15.46.

While all these companies are currently destroying value to fund growth, Stoke Therapeutics' ratio of -4.63 is the highest, or least negative, in the group. This indicates that, relative to its competitors, Stoke Therapeutics demonstrates a stronger handle on its capital efficiency at its current stage of development.